{"Clinical Trial ID": "NCT00086957", "Intervention": ["INTERVENTION 1:", "Phase I: Dose Level 1 - Docetaxel 75 mg/m^2", "Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1) and docetaxel 75 mg/m^2 intravenously every 3 weeks.", "INTERVENTION 2:", "Phase I: Dose Level 2 - Docetaxel 60 mg/m^2", "Subjects receive gefitinib 250 mg orally daily, trastuzumab 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1) and docetaxel 60 mg/m^2 intravenously every 3 weeks."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Adenocarcinoma of the breast confirmed histologically", "Metastatic diseases", "- HER-2/neu overexpression (3+ by OR 2+ immunohistochemistry by fluorescence hybridization in situ)", "A measurable or evaluable disease", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age", "- 18 years and over", "Gender", "Men or women", "Status of menopause", "Unspecified", "State of play", "- ECOG 0-2", "Life expectancy", "Unspecified", "Haematopoietic", "Absolute number of granulocytes 1,500/mm^3", "Number of platelets 100 000/mm^3", "Hepatic", "AST and ALT < 2.5 times the upper limit of normal (ULN) (5.0 times the ULN in the presence of liver metastases)", "Bilirubine < 1.5 times LSN", "No unstable or uncompensated liver disease", "Renal", "Creatinine < 1.6 mg/dL", "No unstable or uncompensated kidney disease", "Cardiovascular disorders", "LVEF > 45% by echocardiogram or MUGA", "No previous New York Heart Association Heart Disease Class I-IV", "No extended PR interval or auriventricular block on ECG", "No unstable or uncompensated heart disease", "Pulmonary", "No unstable or uncompensated respiratory disease", "No clinically active interstitial pulmonary disease", "Patients who are asymptomatic and have stable chronic radiographic changes are allowed.", "Immunological", "No autoimmune disorders", "No condition of immunosuppression", "No severe hypersensitivity to taxane, gefitinib or any of its excipients", "Other", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "No other prior or concomitant malignancy in the past 5 years, with the exception of basal cell carcinoma or in situ cervix carcinoma", "No other serious or uncontrolled systemic disease", "No other acute or chronic disease that would prevent participation in the study", "No other major clinical disorder or laboratory finding that would prevent participation in the study", "No psychiatric illness that would prevent compliance with the study", "THERAPE PRIOR CONCURENT:", "Biological therapy", "If > 6 months have elapsed before the recurrence of the disease, the prior adjuvant trastuzumab (Herceptin\u00ae) may be used.", "No anterior trastuzumab for metastatic breast cancer", "No previous monoclonal antibodies directed against the epidermal growth factor receptor (EGFR)", "- Chemotherapy", "Previous adjuvant chemotherapy (or first-line treatment for metastatic breast cancer) has been authorized.", "A prior adjuvant taxan is allowed if completed > 6 months prior to diagnosis of metastatic breast cancer", "No prior docetaxel for metastatic breast cancer", "Endocrinotherapy", "Prior adjuvant hormone therapy (or first-line treatment for metastatic breast cancer) is allowed.", "No concomitant hormonal treatment", "\u2022 Allowable steroid competitor provided the dose is stable", "Radiotherapy", "Unspecified", "Surgery", "Fully recovered from an oncological operation or other previous major operation", "No concomitant surgery within 7 days of administration of gefitinib", "Other", "Retrieved from previous anticancer treatment (alopecia authorised)", "More than 30 days since prior authorization of a drug or research officer", "No previous treatment with EGFR (i.e. tyrosine kinase inhibitors)", "No concomitant use of any of the following medicinal products:", "Phenytoin", "- Carbamazepine", "- Barbiturates", "- Rifampin", "Hypericum perforatum (St John's wort)", "No other concomitant anticancer treatment", "No concomitant cardioprotective medicines", "No concomitant oral retinoids", "Simultaneous participation in the trastuzumab imaging study of the city of Hope's indium allowed"], "Results": ["Performance measures:", "Number of participants with at least one dose limiting toxicity in Phase I", "Dose Limiting Toxicity (DLT) defined as any treatment-related Grade 3 or higher DLT, with the exception of haematological toxicity that must be grade 4.", "Duration: 4 weeks from the start of treatment, up to 2 years", "Results 1:", "Title of arm/group: Phase I: Dose Level 1 - Docetaxel 75 mg/m^2", "Subjects are given 250 mg of gefitinib orally daily, 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1) and 75 mg/m^2 intravenously every 3 weeks.", "Total number of participants analysed: 2", "Type of measurement: Number", "Unit of measurement: participants with DLT 2", "Results 2:", "Title of arm/group: Phase I: Dose Level 2 - Docetaxel 60 mg/m^2", "Subjects are given 250 mg of gefitinib orally daily, 6 mg/kg intravenously every 3 weeks (after an initial dose of 8 mg/kg with cycle 1) and 60 mg/m^2 intravenously every 3 weeks.", "Total number of participants analysed: 7", "Type of measurement: Number", "Unit of measurement: participants with DLT 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/2 (100.00 per cent)", "Febrile neutropenia * 2/2 (100.00 %)", "Hemorrhage NOS * 0/2 (0.00 %)", "Abdominal pain * 0/2 (0.00 %)", "Diarrhoea * 0/2 (0.00 %)", "Melaena * 0/2 (0.00 %)", "Oral mucositis * 0/2 (0.00 %)", "Nausea * 0/2 (0.00 %)", "Vomiting * 0/2 (0.00 %)", "- Catheter-related infection * 0/2 (0.00 %)", "\u2022 NOS infection * 0/2 (0.00 %)", "Leucopenia * 1/2 (50%)", "Adverse Events 2:", "Total: 7/29 (24.14 per cent)", "Febrile neutropenia * 1/29 (3.45%)", "- Hemorrhage NOS * 1/29 (3.45%)", "Abdominal pain * 1/29 (3.45%)", "Diarrhoea * 2/29 (6.90 per cent)", "Melaena * 1/29 (3.45%)", "* 1/29 (3.45%)", "Nausea * 1/29 (3.45%)", "Vomiting * 1/29 (3.45%)", "* 1/29 (3.45%)", "* 2/29 (6.90 per cent)", "Leucopenia * 0/29 (0.00 %)"]}